Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results Read more about Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 Read more about Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results Read more about Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 Read more about Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference Read more about Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Protalix BioTherapeutics Issues 2024 Letter to Stockholders Read more about Protalix BioTherapeutics Issues 2024 Letter to Stockholders
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results Read more about Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 Read more about Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel Read more about Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors Read more about Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors